Sutro Biopharma: Difference between revisions

Revision as of 21:52, 29 December 2024

Sutro Biopharma

Type	Public
Industry	Biotechnology
Website	[www.sutrobio.com Official website]

Sutro Biopharma is a biotechnology company based in South San Francisco, California. The company specializes in the development of therapeutics for the treatment of cancer and other serious diseases. Sutro Biopharma utilizes a proprietary cell-free protein synthesis technology to develop its products.

History

Sutro Biopharma was founded in 2003. The company has focused on developing a platform for the rapid and efficient production of complex biologics, including antibody-drug conjugates (ADCs) and bispecific antibodies.

Technology

Sutro's cell-free protein synthesis platform allows for the precise and rapid production of proteins. This technology is particularly useful in the development of ADCs, which are designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy cells.

Products and Pipeline

Sutro Biopharma is actively developing a pipeline of therapeutic candidates. The company's lead product candidates include:

STRO-001: An ADC targeting CD74, being developed for the treatment of hematologic malignancies.
STRO-002: An ADC targeting folate receptor alpha, being developed for the treatment of ovarian cancer and other solid tumors.

Collaborations

Sutro Biopharma has established collaborations with several major pharmaceutical companies to advance its technology and product candidates. These collaborations include partnerships with companies such as Merck & Co., Bristol-Myers Squibb, and EMD Serono.

References

External links

Official website

@@ Line 1: / Line 1: @@
-[[File:Sutro Biopharma Inc logo.png|thumb|Sutro Biopharma Inc logo]] '''Sutro Biopharma''' is a biotechnology company focused on the development of novel cancer therapies. It utilizes a proprietary cell-free protein synthesis platform, which allows for the rapid design and development of [[monoclonal antibodies]], antibody-drug conjugates (ADCs), and other [[protein therapeutics]]. The company's technology enables precise control over the design and engineering of therapeutic proteins, potentially leading to more effective and safer treatments for patients.
-==History==
+{{Infobox company
-Sutro Biopharma was founded with the goal of revolutionizing the way therapeutic proteins and [[antibodies]] are discovered, developed, and manufactured. Over the years, the company has established itself as a leader in the field of synthetic biology and protein engineering, attracting attention from both the scientific community and the biopharmaceutical industry.
+| name = Sutro Biopharma
+| logo =
+| type = Public
+| industry = Biotechnology
+| founded = 2003
+| founder =
+| headquarters = South San Francisco, California, United States
+| key_people =
+| products =
+| revenue =
+| num_employees =
+| website = [https://www.sutrobio.com www.sutrobio.com]
+}}
-==Technology==
+'''Sutro Biopharma''' is a [[biotechnology]] company based in [[South San Francisco, California]]. The company specializes in the development of [[therapeutics]] for the treatment of [[cancer]] and other serious diseases. Sutro Biopharma utilizes a proprietary [[cell-free protein synthesis]] technology to develop its products.
-The core of Sutro Biopharma's technology is a cell-free protein synthesis platform, which differs from traditional methods that rely on living cells to produce proteins. This approach offers several advantages, including the ability to incorporate non-natural amino acids into proteins, improved control over protein folding and assembly, and the elimination of the risk of contamination associated with cell-based systems.
-==Product Pipeline==
+== History ==
-Sutro Biopharma's product pipeline includes a variety of candidates in different stages of development, primarily focused on oncology. These candidates leverage the company's platform to target specific mechanisms involved in cancer progression and resistance. Among the most advanced candidates are novel ADCs designed to deliver cytotoxic agents directly to cancer cells, minimizing the impact on healthy tissues.
+Sutro Biopharma was founded in 2003. The company has focused on developing a platform for the rapid and efficient production of complex biologics, including [[antibody-drug conjugates]] (ADCs) and [[bispecific antibodies]].
-==Collaborations==
+== Technology ==
-Recognizing the potential of its platform, Sutro Biopharma has entered into several strategic collaborations with major pharmaceutical companies. These partnerships aim to accelerate the development and commercialization of its pipeline candidates and to explore new applications of its technology in other therapeutic areas.
+Sutro's cell-free protein synthesis platform allows for the precise and rapid production of proteins. This technology is particularly useful in the development of ADCs, which are designed to deliver cytotoxic agents directly to [[cancer cells]], minimizing damage to healthy cells.
-==Challenges and Opportunities==
+== Products and Pipeline ==
-As with any biotechnology company, Sutro Biopharma faces challenges, including the high costs of drug development, regulatory hurdles, and the need to demonstrate the safety and efficacy of its candidates in clinical trials. However, the unique capabilities of its platform and its focus on unmet medical needs in oncology present significant opportunities for growth and success in the competitive biopharmaceutical landscape.
+Sutro Biopharma is actively developing a pipeline of therapeutic candidates. The company's lead product candidates include:
+* '''STRO-001''': An ADC targeting [[CD74]], being developed for the treatment of [[hematologic malignancies]].
+* '''STRO-002''': An ADC targeting [[folate receptor alpha]], being developed for the treatment of [[ovarian cancer]] and other [[solid tumors]].
-[[Category:Biotechnology companies]]
+== Collaborations ==
-[[Category:Pharmaceutical industry]]
+Sutro Biopharma has established collaborations with several major pharmaceutical companies to advance its technology and product candidates. These collaborations include partnerships with companies such as [[Merck & Co.]], [[Bristol-Myers Squibb]], and [[EMD Serono]].
-[[Category:Cancer research]]
-{{pharmacology-stub}}
+== See also ==
+* [[Biotechnology]]
+* [[Antibody-drug conjugate]]
+* [[Cancer treatment]]
+== References ==
+<references />
+== External links ==
+* [https://www.sutrobio.com Official website]
+[[Category:Biotechnology companies of the United States]]
+[[Category:Companies based in South San Francisco, California]]
+[[Category:Companies established in 2003]]
+[[Category:Biopharmaceutical companies]]